Regorafenib (Stivarga)

The U.S. Food and Drug Administration expanded the indications of regorafenib (STIVARGA, Bayer HealthCare Pharmaceuticals Inc.) to include the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

 

Related Article: FDA expands approved use of Stivarga to treat liver cancer.



No comments have been posted yet.